Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenyang Liu

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Science (New York, N.Y.)|May 28, 2026
Stabilizing in-transition phases of superlattices through shape control of silver nanocrystalsYasutaka Nagaoka, Timothy C Moore, Arseniy Epishin, et al.
Cancer Communications (London, England)|October 24, 2024
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 studyYun Liu, Yanfeng Wang, Yanrong Zhu, et al.
Science (New York, N.Y.)|March 9, 2013
A transforming metal nanocomposite with large elastic strain, low modulus, and high strengthShijie Hao, Lishan Cui, Daqiang Jiang, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon ResponsesChunfeng Li, Shulong Zu, Yong-Qiang Deng, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Science (New York, N.Y.)|May 28, 2026
Stabilizing in-transition phases of superlattices through shape control of silver nanocrystalsYasutaka Nagaoka, Timothy C Moore, Arseniy Epishin, et al.
Cancer Communications (London, England)|October 24, 2024
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 studyYun Liu, Yanfeng Wang, Yanrong Zhu, et al.
Science (New York, N.Y.)|March 9, 2013
A transforming metal nanocomposite with large elastic strain, low modulus, and high strengthShijie Hao, Lishan Cui, Daqiang Jiang, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon ResponsesChunfeng Li, Shulong Zu, Yong-Qiang Deng, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 9